Consorci D'atencio Primaria De Salut Barcelona Esquerra
- Address
- lock Available on a paid plan
Respiratory Tract Diseases and Chronic Obstructive Pulmonary Disease
At Consorci D'atencio Primaria De Salut Barcelona Esquerra, research in respiratory medicine focuses on improving day-to-day disease control for people living with Chronic Obstructive Pulmonary Disease. The studies are designed to assess whether newer treatment approaches can offer better symptom stability and overall clinical control than standard care.
- Evaluating treatment effectiveness in COPD
- Improving clinical control and symptom stability
- Comparing established respiratory therapies for high-risk patients
This work reflects a practical focus on helping patients manage chronic breathing problems more effectively in everyday care.
Bacterial Infections and Mycoses with a focus on Invasive Extraintestinal Pathogenic Escherichia coli Disease
The site also contributes to research in infectious diseases, especially studies aimed at preventing serious bacterial illness caused by Escherichia coli. These trials are assessing a vaccine strategy intended to reduce the risk of invasive disease in older adults with a history of urinary tract infection.
- Prevention of invasive E. coli disease
- Testing a vaccine approach against key bacterial serotypes
- Reducing serious bloodstream and sterile-site infections
By focusing on prevention, this research seeks to lower the burden of severe bacterial infections in a vulnerable population.
Virus Diseases and Respiratory Syncytial Virus Infections
Clinical research at this Barcelona site includes studies on respiratory viral infections, particularly Respiratory Syncytial Virus. The trials are designed to evaluate the immune response and safety of vaccination in older adults, with the goal of strengthening protection before seasonal exposure.
- Assessing immune response to RSV vaccination
- Supporting prevention of seasonal viral respiratory illness
- Studying vaccine protection in adults aged 60 years and older
This area of research is especially relevant for improving prevention of respiratory infections that can be more serious in older people.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Novo Nordisk A/S1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Consorci D'atencio Primaria De Salut Barcelona Esquerra
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Controlled Trial Comparing the Efficacy of Umeclidinium Bromide, Fluticasone Furoate, and Vilanterol Versus LABA-LAMA Combination in High-Risk COPD Patients | Fundacio Privada Mon Clinic Barcelona | Phase III | Not Recruiting | Feb 2024 | Jan 2025 |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aclidinium Bromide | 1 | Unknown | 2024-02-09 | 2024-02-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.